Deupsilocin vs Lysergide tartrate (LSD)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Major Depressive Disorder
Shared mechanism: 5-HT2A receptor · full Major Depressive Disorder pipeline
Deupsilocin
Developed by Helus Pharma
NCT05385783 · Phase 1/2 · completed
The study randomized 57 participants and used quadruple masking, with placebo comparator sessions in both the major depressive disorder and healthy-participant groups. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Registered primary outcomes are safety measures; the MADRS result is the sponsor-designated primary efficacy endpoint from topline press releases, not yet peer reviewed. Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: June 2027 · NCT06793397 (registry estimate)
Reported efficacy
Adverse Events (All Arms) (Day 1 thru End of Study Visit (which is: Day 56 Arms A & B; Day 28 Arms C & D; Day 35 Arms E)); Resting 12 Lead ECG ventricular rate (Arms A & B) (Screening, Day -1, Day 1, Day 2, Day 21, Day 22, & Day 23); Resting 12 Lead ECG ventricular rate (Arms C & D) (Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9); Resting 12 Lead ECG ventricular rate (Arms E) (Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16); Resting 12 Lead ECG PR interval (Arms A & B) (Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23); Resting 12 Lead ECG PR interval (Arms C & D) (Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9); Resting 12 Lead ECG PR interval (Arms E) (Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16); Resting 12 Lead ECG QRS duration (Arms A & B) (Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23); Resting 12 Lead ECG QRS duration (Arms C & D) (Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9); Resting 12 Lead ECG QRS duration (Arms E) (Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16); Resting 12 Lead ECG QT interval (Arms A & B) (Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23); Resting 12 Lead ECG QT interval (Arms C & D) (Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9); Resting 12 Lead ECG QT interval (Arms E) (Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16); Resting 12 Lead ECG QTcF (Arms A & B) (Screening, Day -1, Day 1, Day 2, Day 21, Day 22, Day 23); Resting 12 Lead ECG QTcF (Arms C & D) (Screening, Day -1, Day 1, Day 2, Day 7, Day 8, & Day 9); Resting 12 Lead ECG QTcF (Arms E) (Screening, Day -1, Day1, Day 2, Day 7, Day 8, Day 9, Day 14, Day 15, Day 16); Holter monitoring (Arms A & B) (Day -1, Day 1, Day 22); Holter monitoring (Arms C & D) (Day -1, Day 1, Day 8); Holter monitoring (Arm E) (Day -1, Day 1, Day 8, Day 15); Columbia Suicide Severity Rating Scale (CSSRS) Lifetime version (All Arms) (Screening); Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms A & B) (Day -1, Day 2, Day 10, Day 17, Day 21, Day 23, Day 31, Day 38, Day 42, and Day 56); Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arms C & D) (Day -1, Day 2, Day 7, Day 9, Day 15, Day 21, Day 28); Columbia Suicide Severity Rating Scale (CSSRS) Since Last Visit (SLV) (Arm E) (Day -1, Day 2, Day 7, Day 9, Day 14, Day 16, Day 21, Day 28, Day 35): Primary endpoint (3-week MADRS change vs placebo): -14.08 point difference after a single 12mg dose (p=0.0005, Cohen's d=2.151) (met)
Result source: NCT05385783
Lysergide tartrate (LSD) · DT120
Developed by Definium Therapeutics
NCT06941844 · Phase 3 · active, not recruiting
Participants were randomized and the study was triple-blinded (participant, investigator, and outcomes assessor) against a placebo comparator, which minimizes bias from expectation effects common in psychedelic trials. The primary endpoint, change in a validated clinical depression severity scale (MADRS) at Week 6, showed a large and statistically significant improvement for the drug versus placebo (p<0.0001), meeting the pre-specified comparison in the favorable direction.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: September 2027 · NCT07592689 (registry estimate)
Reported efficacy
Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6 (Baseline to Week 6): Emerge (NCT06941844), primary endpoint LS mean change in MADRS total score at Week 6: DT120 ODT 100 µg -13.3 vs placebo -5.2; LS mean difference -8.1 points; p<0.0001. (met)
Result source: NCT06941844
Results for Major Depressive Disorder
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Deupsilocin | Lysergide tartrate (LSD) |
|---|---|---|
| MADRS, change (acute) | —Not posted · NCT06564818 | —Trial running · NCT06941844 |
| CGI-S, change (acute) | —Not posted · NCT06564818 | —Trial running · NCT06941844 |
| MADRS response | —Not posted · NCT06564818 | —Trial running · NCT06941844 |
| MADRS remission | —Not posted · NCT06564818 | —Trial running · NCT06941844 |
| Relapse (% of patients) | —Not posted · NCT06564818 | —Trial running · NCT06941844 |
MADRS, change (acute)
- Deupsilocin
- —Not posted · NCT06564818
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
CGI-S, change (acute)
- Deupsilocin
- —Not posted · NCT06564818
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
MADRS response
- Deupsilocin
- —Not posted · NCT06564818
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
MADRS remission
- Deupsilocin
- —Not posted · NCT06564818
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
Relapse (% of patients)
- Deupsilocin
- —Not posted · NCT06564818
- Lysergide tartrate (LSD)
- —Trial running · NCT06941844
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Deupsilocin's landscape · Lysergide tartrate (LSD)'s landscape